SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus gets USFDA’s nod for Atorvastatin Calcium Tablets, Dimethyl Fumarate Delayed-Release Capsules

22 Nov 2018 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Atorvastatin Calcium Tablets in the strengths of 10 mg, 20 mg, 40 mg and 80 mg (US RLD —Lipitor). It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Atorvastatin is used along with a proper diet to help lower ‘bad’ cholesterol and fats (such as LDL, triglycerides) and raise ‘good’ cholesterol (HDL) in the blood. It belongs to a group of drugs known as ‘statins.’ It works by reducing the amount of cholesterol made by the liver. Lowering ‘bad’ cholesterol and triglycerides and raising ‘good’ cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks.

The group also received a tentative approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg (US RLD-TECFIDERA capsules). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Dimethyl Fumarate is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

The group now has 233 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

938.90 -1.20 (-0.13%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×